Targeted therapy and radiation for HER2-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a targeted medicine (trastuzumab rezetecan) combined with radiation therapy for people with HER2-mutant non-small cell lung cancer that has only a few spots of growth. The goal is to see if this combination controls the cancer and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your lung cancer must have a HER2 gene change (found through a blood or tissue test).
- Your cancer must have grown in only a few spots (1 to 5) after responding to your last treatment for at least 6 months.
- You must have had at least one line of chemotherapy with a platinum drug (like carboplatin or cisplatin).
- You must be able to have radiation therapy safely on all the growing spots, which are not in the brain.
- You must be generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medications, trastuzumab rezetecan and adebrelimab, given alone or together, for people with a specific type of stage III lung cancer that has a HER2 change. The goal is to see if these treatments can help control the cancer after standard chemotherapy and radiation.
This trial tests a combination of two study drugs for a type of lung cancer that has a specific genetic change (HER2). Doctors want to see if this combination can help treat the cancer when it is advanced.
This trial tests a combination of two drugs, adebrelimab and trastuzumab rezetecan, for people with stage III lung cancer that cannot be removed by surgery and has a specific genetic change called HER2. The goal is to see if this combination shrinks tumors and helps patients live longer.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests combining two targeted therapies (an EGFR inhibitor and a HER2-targeted drug) for advanced lung cancer that has both an EGFR mutation and a HER2 change. The goal is to see if this combination works better than current treatments.
This trial tests a drug called trastuzumab deruxtecan (an antibody-drug conjugate) in people with advanced non-small cell lung cancer that has high levels of HER2. The drug is designed to target and kill cancer cells while sparing healthy cells, and the study will see how well it works and how safe it is.
Hear when a new HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.